Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics, and the SEER news feed reflects that focus. Company press releases highlight how Seer’s Proteograph Product Suite—combining proprietary engineered nanoparticles, automation instrumentation, consumables, and analytical software—is being used in large-scale and translational research across cardiovascular disease, oncology, aging biology, and other areas of human health.
Investors and researchers following SEER news will find regular updates on financial results, platform launches, and scientific validation. Seer’s quarterly earnings announcements describe revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects, along with commentary on adoption of its platform and the growth of third-party publications and preprints that use its technology.
The news stream also covers Seer’s presence at major scientific and investor conferences. Releases detail presentations at meetings such as the Human Proteome Organization World Congress and the American Society of Human Genetics, where independent and collaborative studies showcase applications of the Proteograph platform in deep plasma proteomics, biomarker discovery, proteogenomics, and multi-omic precision medicine research. Other items include participation in healthcare and life sciences investor conferences, as well as board and governance updates.
For those tracking how proteomics technologies are being deployed in population-scale and translational studies, Seer’s news provides insight into collaborations, such as population-scale proteomics projects and genome-wide association studies using the Proteograph platform. Bookmarking the SEER news page offers a centralized view of Seer’s financial disclosures, scientific milestones, and corporate developments as reported in its official communications.
Seer, Inc. (Nasdaq: SEER) has appointed Deep Nishar and Dr. Mostafa Ronaghi to its Board of Directors, effective February 13, 2020. Nishar, a Senior Managing Partner at SoftBank, has extensive experience in tech companies such as Google and LinkedIn. Dr. Ronaghi is a former CTO of Illumina and co-founder of Grail. Their appointments aim to enhance Seer’s leadership in the proteomics field, promoting innovative approaches to biological insights and market expansion. The company's Proteograph™ Product Suite aims to provide deep, unbiased proteomics analysis, advancing scientific outcomes.
Seer, a life sciences company, announced the closing of a public offering of 3,750,000 shares of Class A common stock at $67.00 per share, generating $251.25 million before commissions. In this offering, Seer sold 1,650,000 shares while 2,100,000 shares were sold by existing stockholders. The offering was managed by J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. The SEC approved the offering on January 27, 2021. The funds raised will be used to enhance Seer's proteomics platform, including the Proteograph Product Suite.
Seer, a life sciences company, has announced a public offering of 3,750,000 shares of Class A common stock at $67.00 per share. The offering includes 1,650,000 shares from Seer and 2,100,000 from selling stockholders. There is a 30-day option for underwriters to purchase an additional 562,500 shares. The offering is expected to close around February 1, 2021. Major investment banks involved are J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. Seer will not receive proceeds from selling stockholders' shares.
Seer, Inc. announced a proposed underwritten public offering of 3,500,000 shares of Class A common stock, with 1,400,000 shares offered by the company and 2,100,000 shares by selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 525,000 shares. Proceeds will support the commercialization and development of the Proteograph Product Suite and may also fund potential acquisitions. The offering's completion is subject to market conditions, and no assurance is given regarding timing or terms.
Seer (NASDAQ: SEER) has announced a non-exclusive commercial agreement with Thermo Fisher Scientific, enabling the integration of Thermo Fisher’s Orbitrap mass spectrometry systems with Seer’s Proteograph Product Suite. This collaboration aims to enhance end-to-end proteomics workflows, helping researchers achieve unbiased, deep proteome analysis. With both companies committed to advancing proteomics in emerging fields like proteogenomics, the combined solution will be readily available, reflecting a significant step toward expanding proteomics accessibility in various scientific markets.
Seer, a life sciences company, announced a non-exclusive agreement with Bruker Corporation to market the timsTOF Pro mass spectrometer alongside its Proteograph Product Suite. This collaboration aims to create an integrated proteomics solution that enhances accessibility for researchers. The Proteograph enables deep and rapid analysis of thousands of proteins, making it suitable for large-scale studies. Leaders from both companies emphasize the partnership’s potential to accelerate the adoption of unbiased proteomics workflows across various applications.
Seer, Inc. (Nasdaq: SEER), a life sciences company, will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:40 a.m. PT. The event will feature a presentation and Q&A session with company management. A live webcast will be accessible through the Investor section of Seer's website, with an archived replay available post-conference.
Seer focuses on delivering unbiased, rapid, and scalable proteomics information, primarily through its Proteograph™, enhancing scientific research efficiency.
Seer, a life sciences company, successfully closed its initial public offering (IPO) with 10,592,106 shares of Class A common stock priced at $19.00 per share, raising approximately $201.3 million. The IPO includes the full exercise of underwriters' options for an additional 1,381,579 shares. Seer's stock began trading on the Nasdaq under the ticker symbol SEER on December 4, 2020. The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley.